0001029142
false
0001029142
2024-08-01
2024-08-01
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 01, 2024
Dynavax Technologies Corporation
(Exact name of Registrant as Specified in Its Charter)
Delaware 001-34207 33-0728374
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
2100 Powell Street, Suite 720
Emeryville 94608
,
California
(Address of Principal Executive Offices) (Zip Code)
Registrant's Telephone Number, Including Area Code:
510
848-5100
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Name of each exchange on which registered
Symbol(s)
Common Stock, $0.001 par value DVAX Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 ((s)/230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ((s)/240.12b-2
of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a)
of the Exchange Act.
-------------------------------------------------------------------------------
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Effective August 1, 2024, the Board of Directors of Dynavax Technologies
Corporation (the "Company") re-appointed Kelly MacDonald to serve as the
Company's Chief Financial Officer (principal financial officer) upon her
return from maternity leave. During said leave, Ryan Spencer, the Company's
current Chief Executive Officer (principal executive officer) ("CEO") also
temporarily served as Interim Chief Financial Officer (principal financial
officer) ("CFO"). Upon Ms. MacDonald's return, Mr. Spencer will no longer
serve as Interim CFO but continues as CEO.
There will be no change in Ms. MacDonald's compensation as a result of this
re-appointment. Biographical information for Ms. MacDonald is available in the
Company's proxy statement filed with the Securities and Exchange Commission on
April 11, 2024 in connection with the Company's 2024 annual meeting of
stockholders, such information being incorporated herein by reference.
-------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Dynavax Technologies Corporation
Date: August 2, 2024 By: /s/ Ryan Spencer
Ryan Spencer
Chief Executive Officer
-------------------------------------------------------------------------------
{graphic omitted}
{graphic omitted}